Similarly, the commercially available JAK1/2 inhibitor, ruxolitinib, was previously applied to CD19 CAR-T cells against JAK-mutant B-ALL to achieve an additive effect on tumor cells and CD19-directed immunotherapy [11]. Here, JAK1 is linked to neoplasm.